touchCONGRESS Webinar

Introduction

Stay up-to-date with the latest developments in CDK4/6 inhibition for advanced breast cancer with our expert summary from the ESMO Breast Cancer Congress in Berlin, Germany, 2–4 May 2019.

Professor Sibylle Loibl (University of Frankfurt and Chief Executive Officer and Chair of the German Breast Group) reviews the most important emerging data presented at the ESMO Breast Cancer Congress in Berlin, Germany, 2–4 May 2019 and discusses their potential impact for treating patients with HR+/HER2- advanced breast cancer.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching this touchCONGRESS Webinar, you should be able to:

Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognise the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits

Download Slides

Introduction (disclosures, disclaimer, overview)

ESMO Breast Cancer Congress 2019 – Latest findings on the role of CDK4/6 inhibitors

ESMO Breast Cancer Congress 2019 – What does the future hold for patient identification and selection?

ESMO Breast Cancer Congress 2019 – What does the future hold for treatment management in the advanced setting?

Clinical Spotlight

What are the latest results for CDK4/6 inhibitors in patients with advanced HR+/HER2- breast cancer? Focus on optimal use and the management of adverse events
How can treatment be personalized for patients with metastatic HR+/HER2- breast cancer? Focus on mutational analysis for patient selection
How is the management of patients with advanced HR+/HER2- breast cancer evolving? Focus on assessing treatment response and managing outcomes

Please feedback on this touchCONGRESS Webinar on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).

Prof. Sibylle Loibl

Sibylle Loibl, MD, PhD, is the Chief Executive Officer and Chair of the German Breast Group (GBG), one of the leading study groups worldwide. She devotes the majority of her time to clinical trial research at the GBG and at her clinical affiliations: the University of Frankfurt, and Oncology Bethanien in Frankfurt.
Prof. Loibl is an associate professor at the University of Frankfurt. She graduated from the University of Heidelberg and completed her fellowship and residency as a gynaecologist and obstetrician at the Universities of Heidelberg and Frankfurt.
Prof. Loibl is internationally renowned in the fields of neoadjuvant breast cancer, breast cancer during pregnancy, and breast cancer in young women. She developed the translational research division within the GBG and has led numerous translational projects as well as research projects funded by the EU Commission. She has led and participated in more than 100 national and international clinical trials in the field of breast cancer.
In 2014, she joined the Executive Board of the Breast International Group (BIG). As a medical expert, she serves on several international steering committees, translational research committees, and independent data monitoring committees.
Prof. Loibl has co-authored almost 300 MEDLINE-listed scientific papers, in addition to more than 200 original and peer-reviewed articles and 30 books or book chapters. She has also actively contributed to more than 200 national and international congresses. She is an active member of numerous national and international organizations such as the American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO).

Disclosures: Honoraria received by my institution from AbbVie, Amgen, AstraZeneca, Celgene,Daiichi, Novartis, Pfizer, PRIME, Roche, Seattle Genetics, Teva and Vifor. Research grants received by my institution: ABGSG, AbbVie, Amgen, AstraZeneca, BIG, Celgene, Cepheid, Myriad, NSABP, Novartis, Pfizer, Roche, Teva and Vifor.